We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A new pricing agreement will allow a leading HIV regimen to be rolled out in more than 90 low- to middle-income countries, at an average cost of $75 per patient, per year. Read More
Sen. Claire McCaskill (D-Mo.) introduced legislation that would bar patent arrangements like the controversial deal between Allergan and a Native American tribe. Read More
It would be obvious to treat a patient with folic acid before administering Lilly’s antifoliate chemotherapy drug Alimta (pemetrexed) to reduce Alimta’s toxic effects, the PTO’s Patent Trial and Appeals Board ruled in a challenge to Lilly. Read More
The Federal Circuit eased the ability for patent holders to amend their claims when challenged under inter partes review — a hurdle that pharmaceutical industry trade groups had previously described as unfair, ambiguous and impractical. Read More
The FDA is streamlining its communications with generics manufacturers, and outlined its procedures for relaying the status of an ANDA review in a new manual for staff. Read More